Completed

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

J1G-MC-LAKA - ClinicalTrials.gov - NCT03720548

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.
How long will I be in the trial?
Part A will last up to 17 weeks and may include up to 14 visits. Part B will last up to 317 days and may include 16 visits.
Email
Completed

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

J1G-MC-LAKA - ClinicalTrials.gov - NCT03720548

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.
How long will I be in the trial?
Part A will last up to 17 weeks and may include up to 14 visits. Part B will last up to 317 days and may include 16 visits.
Email

Key Requirements

Age :

18-85

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-85

Sex

All

Participants must

Participants must NOT

Trial Summary

Conditions the trial is for

Mild Cognitive Impairment, Mild Alzheimer's, Early Symptoms of Alzheimer's Disease, Moderate Alzheimer's

What the trial is testing?

interventions example

Could I receive a Placebo?

yes

Enrollment Goal

100

Trial Dates

November 2018 - May 2019

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-85

Sex

All

Participants must

Participants must NOT

Trial Summary

Conditions the trial is for

Mild Cognitive Impairment, Mild Alzheimer's, Early Symptoms of Alzheimer's Disease, Moderate Alzheimer's

What the trial is testing?

interventions example

Could I receive a Placebo?

yes

Enrollment Goal

100

Trial Dates

November 2018 - May 2019

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Resources

Memory, Alzheimer’s Disease, and Research Studies

Memory, Alzheimer’s Disease, and Research Studies

With the help of research study participants, we are learning about aging, memory, and potential new approaches to fighting Alzheimer’s disease.
Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?